Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Doule Blind, Placebo-controlled, Multiple Dose Escalation Phase 1b Study to Evaluate the Safety and Tolerability of Aolanti Weikang Tablets in Healthy Volunteers

NCT03358485 is registered in ClinicalTrials.gov with Jiangxi Qingfeng Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT03358485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03358485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Doule Blind, Placebo-controlled, Multiple Dose Escalation Phase 1b Study to Evaluate the Safety and Tolerability of Aolanti Weikang Tablets in Healthy Volunteers
Lead sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 14, 2017
Completion date
June 30, 2018
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

functional dyspepsia